热门资讯> 正文
Haemonetics在Needham的血管闭合装置竞赛中降级
2025-12-16 03:56
- 美国血液技术(HAE) 0
- 美森(MATX) 0
- 雅培(ABT) 0
- Needham has downgraded Haemonetics (HAE) to hold from buy and removed its price target on concerns over increasing competition.
- Analyst Mike Matson noted that Abbott (ABT) and privately held Cordis have newer venous closure devices.
- Matson said that his checks indicate that Abbott's Perclose ProStyle and Cordis' MYNX Control venous closure device are eating away at sales of Haemonetics VASCADE MVP/MVP XL closure devices in electrophysiology procedures.
- "While HAE is likely to offset the weaker Interventional Technologies growth in FY26 with stronger Plasma and Blood Management Technologies growth, we do not believe that this is sustainable," he wrote, adding, "We expect Interventional Technologies to limit HAE's FY27 revenue and EPS growth and put consensus estimates at risk."
- Haemonetics is down ~5% in Monday trading.
More on Haemonetics
- Haemonetics Is Still Undervalued, Even After The Rally
- Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
- Intuitive Surgical downgraded as Citi previews 2026 in MedTech
- Haemonetics raises 2026 guidance, projects 7%–10% organic growth ex CSL amid strong plasma and hospital performance
- Seeking Alpha’s Quant Rating on Haemonetics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
